Martingale Asset Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Martingale Asset Management’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-16,306	Closed	-$862K	–	1105
2020 Q3	$862K	Sell	16,306 -20,511	-56%	-$1.27M	0.01%	672
2020 Q2	$2.26M	Buy	36,817 +28,903	+365%	+$1.67M	0.03%	491
2020 Q1	$449K	Buy	+7,914	New	+$451K	0.01%	834

Other funds holding BSTC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Martingale Asset Management's BSTC Position: Q4 2020 in Review

Martingale Asset Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 16,306 shares — an estimated $862K sold.

Martingale Asset Management first reported a position in BSTC in Q1 2020 and held it in 3 quarters. The position peaked at $2.26M in Q2 2020. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.

Martingale Asset Management reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
Martingale Asset Management sold 16,306 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $862K.
Martingale Asset Management first reported a position in BioSpecifics Technologies Corp. in Q1 2020 and held it in 3 quarters.
Martingale Asset Management's BioSpecifics Technologies Corp. position peaked at $2.26M in Q2 2020.
1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.

Based on Martingale Asset Management's 13F filing for Q4 2020, filed 10 Feb 2021.